Ian Shott, co-founder and CEO of Arcinova, tells the story of how he established a speciality CMO on an historic site and discloses his plans to revolutionise small molecule manufacturing through a combination of continuous process manufacturing and bio-transformation.
How did you come to set up Arcinova and what made the legacy site from Sanofi and Covance in Alnwick a good target for a takeover?
"After spending 25 years looking at how pharmaceuticals are made, my major assertion was that active drug substance has been manufactured according to a process flowsheet that is 450 years old, in 99 percent of all sites globally."
